Targeting nucleocytoplasmic transport in cancer therapy

Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link

doi:10.18632/oncotarget.1457

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting nucleocytoplasmic transport in cancer therapy

Richard Hill _, Bastien Cautain, Nuria de Pedro and Wolfgang Link

PDF | HTML | How to cite

Oncotarget. 2014; 5:11-28. https://doi.org/10.18632/oncotarget.1457

Metrics: PDF 3458 views | HTML 5925 views | ?

Abstract

Richard Hill1,2,*, Bastien Cautain3,*, Nuria de Pedro3 and Wolfgang Link1,2,*

1 Regenerative Medicine Program, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Portugal

2 IBB-Institute for Biotechnology and Bioengineering, Centro de Biomedicina Molecular e Estrutural, Universidade do Algarve, Campus de Gambelas, Faro, Portugal

3 Fundacion MEDINA Parque tecnológico ciencias de la salud, Avd. Conocimiento 3, Granada, Spain

* These authors contributed equally to this work.

Correspondence:

Wolfgang Link, email:

Keywords: Tumor suppressors, Cancer, Anti-cancer therapy, Nuclear export, nuclear import

Received: September 30, 2013 Accepted: November 22, 2013 Published: November 24, 2013

Abstract

The intracellular location and regulation of proteins within each cell is critically important and is typically deregulated in disease especially cancer. The clinical hypothesis for inhibiting the nucleo-cytoplasmic transport is based on the dependence of certain key proteins within malignant cells. This includes a host of well-characterized tumor suppressor and oncoproteins that require specific localization for their function. This aberrant localization of tumour suppressors and oncoproteins results in their their respective inactivation or over-activation. This incorrect localization occurs actively via the nuclear pore complex that spans the nuclear envelope and is mediated by transport receptors. Accordingly, given the significant need for novel, specific disease treatments, the nuclear envelope and the nuclear transport machinery have emerged as a rational therapeutic target in oncology to restore physiological nucleus/cytoplasmic homeostasis. Recent evidence suggests that this approach might be of substantial therapeutic use. This review summarizes the mechanisms of nucleo-cytoplasmic transport, its role in cancer biology and the therapeutic potential of targeting this critical cellular process

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1457

Publication Alerts

Reviews:

Targeting nucleocytoplasmic transport in cancer therapy

Abstract